Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, multicentre, parallel-group study to
assess the cognitive effects of lurasidone in bipolar I and II patients (manic depression)
who are in remission from an episode. Participants who show cognitive impairment at the
screening visit will be enrolled into the study and randomized at the baseline visit to
receive either lurasidone or placebo adjunctive therapy in a 1:1 ratio for 6 weeks.